Elite Pharmaceuticals (ELTP) investor relations material

Executive summary

• Achieved record revenues of $149 million for fiscal 2026, a 77% increase year-over-year, marking the fifth consecutive year of strong growth.

• Operating income reached $49.1 million, up 151% from the prior year, with profits quadrupling since the Elite label launch.

• Growth driven by full-year contribution from Lisdexamfetamine and new product launches including Oxycodone Acetaminophen, Naltrexone, Phentermine tablets, and expanded manufacturing.

• Company is evaluating strategic alternatives, including M&A and uplisting to Nasdaq, while maintaining operational focus and shareholder value.

Financial highlights

• Revenue increased to $149 million from $84 million year-over-year, a 77% rise.

• Operating income rose to $49.1 million from $20 million, a 151% increase.

• Operating cash flow was $23.7 million, up from $7.5 million, a 219% increase.

• Cash balance grew to $29.8 million, up $18.5 million from last year.

• Working capital nearly doubled to $95 million, and long-term debt reduced by 20%.

Outlook and guidance

• All fundamentals for growth are in place, with infrastructure, product development, and pipeline on schedule.

• Continued focus on launching new products and expanding market share in key generics.

• Evaluating facility expansion to support future growth and potential partnerships.

• Strategic options under review: M&A, Nasdaq uplisting, or continued independent growth.

• Management to discuss recent business developments and future expectations in a scheduled conference call.